Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747247 | 0.98 | TBXAS1 (0.75) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| SCHEMBL2715544 | 0.98 | TBXAS1 (0.75) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| SCHEMBL24844947 | 0.84 | TBXAS1 (1.00) | TBXAS1TDP1L3MBTL1 | |
| SCHEMBL10728648 | 0.84 | TBXAS1 (0.56) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| SCHEMBL16067092 | 0.83 | TBXAS1 (0.68) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| SCHEMBL3040732 | 0.77 | TBXAS1 (0.50) | TBXAS1CYP1A2TDP1L3MBTL1 | |
| SCHEMBL28772279 | 0.73 | TBXAS1 (0.55) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| SCHEMBL1658826 | 0.72 | FES (0.61) | POLBL3MBTL1 | |
| SCHEMBL727185 | 0.72 | CYP1A2 (0.62) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL10665044 | 0.69 | TBXAS1 (0.64) | TBXAS1HRH4HRH3NAPRTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012047664-A1 | ANTI-PECAM THERAPY, COMPOSITIONS, METHODS, AND USES | SUTTER WEST BAY HOSPITAL D/B/A CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2012-04-12 | — | — | WO | claimed |
| US-20120076795-A1 | Anti-PECAM Therapy, Compositions, Methods, and Uses | Sutter West Bay Hospitals D/B/A California Pacific Medical Center (US) | 2012-03-29 | — | — | US | claimed |
| US-6133278-A | PREVENTION AND THERAPY OF CACHEXIA ASSOCIATED WITH CHRONIC DISEASES SUCH AS MALIGNANT TUMOR, TUBERCULOSIS, DIABETES, HEMODYSCRASIA AND ENDOCRINOPATHY, AND AIDS INVOLVING PROGRESSIVE LOSS OF BODY WEIGHT, ANEMIA, EDEMA AND ANOREXIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| EP-0774967-A1 | USE OF QUINONE AND HYDROQUINONE DERIVATIVES FOR THE TEATMENT OF CACHEXIA | Takeda Chemical Industries, Ltd. (JP) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004909-A1 | USE OF QUINONE AND HYDROQUINONE DERIVATIVES FOR THE TEATMENT OF CACHEXIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-22 | — | — | WO | claimed |
| US-5106858-A | For disfunction of heart, brain, lung or kidney | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-21 | — | — | US | claimed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | claimed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | claimed |
| US-10954271-B2 | Anti-microbial peptides | TENSIVE CONTROLS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3194422-B1 | ANTI-MICROBIAL PEPTIDES | TENSIVE CONTROLS INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20200109171-A1 | ANTI-MICROBIAL PEPTIDES | ENDEVICA BIO, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3194422-A1 | ANTI-MICROBIAL PEPTIDES | Tensive Controls Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170081383-A1 | MELANOCORTIN ANALOGS HAVING ENHANCED ACTIVITY AND TRANSPORT | ENDEVICA BIO, INC. | 2017-03-23 | — | — | US | disclosed |
| US-9534018-B2 | Melanocortin analogs having enhanced activity and transport | TENSIVE CONTROLS INC. (US) | 2017-01-03 | — | — | US | disclosed |
| WO-2006014559-A2 | CYCLIC PEPTIDES FOR TREATMENT OF CACHEXIA | PALATIN TECHNOLOGIES, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014676-A1 | Cyclic peptides for treatment of cachexia | PALATIN TECHNOLOGIES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20060014194-A1 | Melanocortin receptor-specific hexapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6133278-A | PREVENTION AND THERAPY OF CACHEXIA ASSOCIATED WITH CHRONIC DISEASES SUCH AS MALIGNANT TUMOR, TUBERCULOSIS, DIABETES, HEMODYSCRASIA AND ENDOCRINOPATHY, AND AIDS INVOLVING PROGRESSIVE LOSS OF BODY WEIGHT, ANEMIA, EDEMA AND ANOREXIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0774967-A1 | USE OF QUINONE AND HYDROQUINONE DERIVATIVES FOR THE TEATMENT OF CACHEXIA | Takeda Chemical Industries, Ltd. (JP) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004909-A1 | USE OF QUINONE AND HYDROQUINONE DERIVATIVES FOR THE TEATMENT OF CACHEXIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014194-A1 | Melanocortin receptor-specific hexapeptides | MC4R, MC3R, MC1R | HRH3 259/4885TBXAS1 2245/4885POLB 3143/4885 |
| US-20060014676-A1 | Cyclic peptides for treatment of cachexia | MC4R, MC3R, MC5R | HRH3 238/4885TBXAS1 2334/4885POLB 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.